Peter Tummino

Bio:

Peter Tummino is the President of Research and Development at Nimbus Therapeutics, where he leads the Discovery, Nonclinical and Clinical groups. Since joining Nimbus as Chief Scientific Officer in 2019, he has been part of the leadership team. In his time at Nimbus, the company has successfully progressed the TYK2 inhibitor NDI-4858 through Phase 2 trials for psoriasis and other immunology indications, advanced the HPK1 inhibitor NDI-101150 through Phase 1b trials in solid tumors, and initiated Phase 1 trials for the WRN inhibitor NDI-219216 in MSI-high solid tumors.

Peter brings over 30 years’ experience in drug discovery across a range of therapeutic areas. Prior to Nimbus, he served as Vice President, Global Head of Lead Discovery at Janssen Pharmaceuticals, leading global discovery operations across multiple therapeutic areas. At GlaxoSmithKline, he held leadership roles including Head of Biology for the Cancer Epigenetics Discovery Performance Unit, progressing first-in-class epigenetic agents into oncology clinical trials. His contributions at GSK included the discovery and progression of several clinical candidates, including the approved oncology drugs dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor), and daprodustat for chronic kidney disease. Earlier, he held scientific positions of increasing responsibility at Warner-Lambert/Parke-Davis, AstraZeneca, and Millennium Pharmaceuticals. He has published 85 peer-reviewed journal articles with over 15,000 citations. Peter earned his B.S. in chemistry from the University of Massachusetts and his Ph.D. from the Department of Biological Chemistry at the University of Michigan, completing a postdoctoral fellowship at Warner-Lambert/Parke-Davis.